Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

L. Albiges · SciRah

Researcher profile · Semantic Scholar

L. Albiges

Share profile

L. Albiges — researcher profile on SciRah

h-index: 77
Works: 577
Citations: 32K

Most-cited papers

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
T. Choueiri, T. Powles, K. Peltola, G. de Velasco +29 more
2024New England Journal of Medicine163 citations
Semantic Scholar
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): results from a double-blind, randomised, phase 3 trial
R. Motzer, P. Russo, Viktor Grünwald, Y. Tomita +18 more
2023The Lancet148 citations Open access
Semantic Scholar
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
T. Choueiri, T. Powles, L. Albiges, M. Burotto +14 more
2023New England Journal of Medicine129 citations Open access
Semantic Scholar
First and Second-line Treatments in Metastatic Renal Cell Carcinoma.
R. Barragán-Carrillo, E. Saad, R. Saliby, Maxine Sun +10 more
2024European Urology86 citations
Semantic Scholar
Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients With Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor: Results of the Phase 3 TiNivo-2 Study
T. Choueiri, L. Albiges, P. Barthélémy, R. Iacovelli +16 more
2024The Lancet66 citations Open access
Semantic Scholar
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes
R. Saliby, C. Labaki, T. Jammihal, Wan-Ling Xie +20 more
2024Cancer Cell53 citations Open access
Semantic Scholar
Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions.
L. Marandino, R. Campi, D. Amparore, Z. Tippu +13 more
2024European Urology Oncology36 citations Open access
Semantic Scholar
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
A. Bamias, A. Stenzl, S. Brown, L. Albiges +27 more
2023European Urology36 citations Open access
Semantic Scholar
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas
O. Alhalabi, J. Thouvenin, S. Négrier, Y. Vano +12 more
2023The Oncologist32 citations Open access
Semantic Scholar
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M. Mantia, Opeyemi A. Jegede, E. Plimack, T. Powles +14 more
2024Journal for ImmunoTherapy of Cancer24 citations Open access
Semantic Scholar
Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.
L. Albiges, A. Bex, C. Suárez, R. Uzzo +9 more
2024Journal of Clinical Oncology22 citations Open access
Semantic Scholar
Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial
Marc-Oliver Grimm, M. Oya, T. Choueiri, R. Motzer +10 more
2023European Urology22 citations Open access
Semantic Scholar
Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).
C. Thibault, A. Flechon, L. Albiges, C. Joly +15 more
2023European Journal of Cancer21 citations Open access
Semantic Scholar
Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors.
N. Menssouri, L. Poiraudeau, C. Helissey, L. Bigot +32 more
2023Clinical Cancer Research21 citations Open access
Semantic Scholar
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma
L. Carril-Ajuria, P. Lavaud, C. Dalban, Sylvie Négrier +18 more
2024European Journal of Cancer20 citations Open access
Semantic Scholar
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial.
M. Voss, H. Gurney, V. Atduev, C. Suárez +16 more
2025European Urology18 citations
Semantic Scholar
Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
R. Motzer, K. Penkov, H. Uemura, M. Campbell +16 more
2024Journal of Clinical Oncology18 citations
Semantic Scholar
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
T. Choueiri, L. Albiges, D. Mcdermott, H. Hammers +21 more
2026Annals of Oncology16 citations Open access
Semantic Scholar
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
M. Velev, C. Dalban, C. Chevreau, G. Gravis +23 more
2023European Journal of Cancer16 citations Open access
Semantic Scholar
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study.
V. Grünwald, A. Bex, S. Rottey, C. Suárez +13 more
2025European Journal of Cancer14 citations Open access
Semantic Scholar
Patients’ Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19
C. Bergerot, J. Malhotra, P. Bergerot, E. Philip +16 more
2023The Oncologist14 citations Open access
Semantic Scholar
Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis.
C. Cerrato, Fabio Crocerossa, M. Marchioni, G. Giannarini +9 more
2024European Urology Oncology13 citations Open access
Semantic Scholar
Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.
L. Albiges, R. Motzer, S. Trevino, R. Kanesvaran +16 more
2025Journal of Clinical Oncology12 citations
Semantic Scholar
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types.
A. Bex, M. Jewett, Bryan Lewis, E. J. Abel +31 more
2025European Urology12 citations
Semantic Scholar
39 Safety profile of belzutifan monotherapy in patients with renal cell carcinoma: A pooled analysis of 4 clinical trials
T. Choueiri, P. Ghatalia, G. de Velasco, L. Albiges +23 more
2024The Oncologist11 citations Open access
Semantic Scholar
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.
T. Powles, T. Choueiri, L. Albiges, K. Peltola +22 more
2025The Lancet Oncology10 citations
Semantic Scholar
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor-based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma.
L. Albiges, T. Powles, Anand Sharma, B. Venugopal +9 more
2025European Urology9 citations Open access
Semantic Scholar
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Stephanie A. Berg, S. La Rosa, Tian Zhang, Phillip M. Pierorazio +20 more
2024Urologic oncology9 citations Open access
Semantic Scholar
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
Jérémie Naffrichoux, P. Poupin, W. Pouillot, C. Linassier +17 more
2024European Journal of Cancer9 citations Open access
Semantic Scholar
First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study.
M. Voss, H. Gurney, V. Atduev, C. Suárez +16 more
2024Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk.
T. Powles, R. Motzer, L. Albiges, C. Suárez +10 more
2023Journal of Clinical Oncology9 citations
Semantic Scholar
Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.
A. Bernard-Tessier, G. Mulier, Paula Nay, C. Baldini +10 more
2023Journal of Clinical Oncology9 citations
Semantic Scholar
Frailty and Renal Cell Carcinoma: Integration of Comprehensive Geriatric Assessment into Shared Decision-making.
Alessio Pecoraro, G. D. Testa, L. Marandino, L. Albiges +10 more
2024European Urology Oncology8 citations Open access
Semantic Scholar
Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?
Catherine C Fahey, Jeffrey Shevach, R. Flippot, L. Albiges +2 more
2023American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting8 citations Open access
Semantic Scholar
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
L. Bigot, J. Sabio, L. Poiraudeau, M. Annereau +28 more
2023European Urology Oncology8 citations
Semantic Scholar
KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).
L. Albiges, C. Suárez, T. Powles, R. Motzer +16 more
2025Journal of Clinical Oncology7 citations
Semantic Scholar
Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
T. Powles, L. Albiges, K. Jalkanen, G. de Velasco +16 more
2024Journal of Clinical Oncology7 citations
Semantic Scholar
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
S. Pal, N. Tannir, P. Grell, Xin Gao +13 more
2024Journal of Clinical Oncology7 citations
Semantic Scholar
GABA promotes resistance to immunotherapy in patients with TLS-positive tumors.
I. Hernández-Verdin, Anne Calvez, Cheng-Ming Sun, A. Bougoüin +23 more
2026Cancer Cell6 citations
Semantic Scholar
Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.
S. George, M. Bourlon, Matías Chacón, H. Cutuli +16 more
2024Journal of Clinical Oncology6 citations Open access
Semantic Scholar
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.
Daniel D. Shapiro, E. J. Abel, L. Albiges, D. Battle +36 more
2025Urologic oncology5 citations
Semantic Scholar
Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohort
N. Jacquin, R. Flippot, J. Masliah-Planchon, G. Grisay +20 more
2024npj Precision Oncology5 citations Open access
Semantic Scholar
Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI).
L. Derosa, Carolina Alves Costa Silva, V. Iebba, B. Routy +16 more
2023Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Cabozantinib in patients (pts) with non-locally pretreated brain metastases (BM) from renal cell carcinoma (RCC): Results of the multicenter CABRAMET phase II trial (NCT03967522).
S. Negrier, L. Mourey, E. Blanc, M. Gross-Goupil +14 more
2025Journal of Clinical Oncology4 citations
Semantic Scholar
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
L. Mourey, L. Rainho, C. Dalban, L. Carril-Ajuria +18 more
2024European Journal of Cancer4 citations
Semantic Scholar
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.
Edwige Baudry, N. Naoun, E. Auclin, C. Saldana +14 more
2023European Journal of Cancer4 citations Open access
Semantic Scholar
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
T. Choueiri, L. Albiges, P. Tomczak, C. Suárez +15 more
2023Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.
Wenxin Xu, B. Rini, L. Albiges, Xiaobin Tang +14 more
2026European Urology3 citations
Semantic Scholar
KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC).
C. Suárez, L. Albiges, K. Beckermann, H. Hammers +16 more
2025Journal of Clinical Oncology3 citations
Semantic Scholar
Phase 1 results of Oncobax-AK in combination with ipilimumab/nivolumab in advanced clear cell renal cell carcinoma (ccRCC; NCT05865730).
L. Derosa, P. Barthélémy, B. Laguerre, F. Barlesi +3 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Powles×16
Invite
T. Powles — researcher profile on SciRah
R. Motzer×11
Invite
R. Motzer — researcher profile on SciRah
T. Choueiri×10
Invite
T. Choueiri — researcher profile on SciRah
C. Suárez×10
Invite
C. Suárez — researcher profile on SciRah

M. Gross-Goupil

×9

Invite

M. Gross-Goupil — researcher profile on SciRah

P. Barthélémy×8

Invite

P. Barthélémy — researcher profile on SciRah

Invite

R. Flippot — researcher profile on SciRah

Invite

M. Burotto — researcher profile on SciRah

Invite

N. Tannir — researcher profile on SciRah

Invite

B. Rini — researcher profile on SciRah

Invite

B. Escudier — researcher profile on SciRah

Invite

C. Chevreau — researcher profile on SciRah